Hector Chinoy Selected Research

Infections

3/2023	Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study.
1/2023	COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey.
1/2019	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hector Chinoy Research Topics

Disease

42	Myositis (Idiopathic Inflammatory Myopathies) 01/2024 - 11/2004
17	Inclusion Body Myositis 01/2024 - 11/2009
16	COVID-19 05/2024 - 01/2021
15	Dermatomyositis (Dermatopolymyositis) 12/2023 - 11/2004
11	Autoimmune Diseases (Autoimmune Disease) 05/2024 - 01/2016
11	Muscular Diseases (Myopathy) 12/2023 - 10/2013
11	Rheumatic Diseases (Rheumatism) 12/2023 - 05/2015
10	Psoriatic Arthritis 01/2024 - 08/2013
10	Neoplasms (Cancer) 12/2023 - 01/2006
9	Polymyositis 11/2023 - 11/2004
9	Rheumatoid Arthritis 11/2023 - 02/2015
7	Necrosis 12/2023 - 11/2009
5	Simian Acquired Immunodeficiency Syndrome 05/2024 - 12/2022
5	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2024 - 01/2006
5	Systemic Scleroderma (Systemic Sclerosis) 11/2023 - 05/2015
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2023 - 02/2014
4	Fatigue 01/2024 - 01/2020
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2023 - 01/2020
4	Muscle Weakness 02/2023 - 10/2013
3	Melanoma (Melanoma, Malignant) 03/2024 - 11/2013
3	Inflammation (Inflammations) 01/2024 - 11/2015
3	Infections 03/2023 - 01/2019
2	Pain (Aches) 01/2023 - 01/2020
2	Connective Tissue Diseases (Connective Tissue Disease) 11/2022 - 01/2020
2	Rhabdomyolysis 12/2019 - 01/2019
2	Vasculitis (Vasculitides) 11/2018 - 01/2017
2	Disease Susceptibility (Diathesis) 01/2006 - 11/2004
1	Obesity 03/2024
1	Gout 03/2024
1	Weight Loss (Weight Reduction) 03/2024
1	Hyperuricemia 03/2024
1	Amyopathic dermatomyositis 03/2024
1	Tuberculosis (Tuberculoses) 03/2024
1	Dermatitis 12/2023
1	Dyspnea (Shortness of Breath) 05/2023
1	Immune System Diseases (Immune Disorders) 05/2023

Drug/Important Bio-Agent (IBA)

23	AutoantibodiesIBA 12/2023 - 10/2007
15	AntibodiesIBA 11/2022 - 01/2006
13	VaccinesIBA 05/2024 - 01/2022
11	COVID-19 VaccinesIBA 05/2024 - 01/2023
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2023 - 10/2013
6	Ligases (Synthetase)IBA 12/2023 - 01/2020
6	Biomarkers (Surrogate Marker)IBA 11/2023 - 11/2013
5	Etanercept (Enbrel)FDA Link 01/2024 - 05/2015
5	Oxidoreductases (Dehydrogenase)IBA 12/2023 - 10/2013
5	Rituximab (Mabthera)FDA Link 11/2023 - 03/2013
5	HLA-DRB1 Chains (HLA DRB1)IBA 02/2023 - 11/2004
4	Adalimumab (Humira)FDA Link 01/2024 - 05/2015
4	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2016
3	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 02/2014
3	Antirheumatic Agents (DMARD)IBA 01/2024 - 01/2017
3	GlucocorticoidsIBA 01/2024 - 01/2021
3	Tumor Necrosis Factor InhibitorsIBA 12/2023 - 01/2016
3	EnzymesIBA 12/2023 - 10/2013
3	Immunologic Factors (Immunomodulators)IBA 05/2023 - 12/2022
3	Immunoglobulin G (IgG)IBA 03/2023 - 05/2019
3	Monoclonal AntibodiesIBA 03/2023 - 02/2018
3	Immunoglobulins (Immunoglobulin)IBA 03/2023 - 01/2019
3	Creatine Kinase (Creatine Phosphokinase)IBA 02/2023 - 01/2020
3	BNT162 VaccineIBA 01/2023 - 10/2022
3	AntigensIBA 01/2021 - 07/2007
3	EpitopesIBA 01/2021 - 04/2016
2	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)IBA 12/2023 - 02/2023
2	tocilizumab (atlizumab)FDA Link 11/2023 - 09/2013
2	Immunosuppressive Agents (Immunosuppressants)IBA 05/2023 - 01/2023
2	Antimalarials (Antimalarial Agents)IBA 05/2023 - 01/2023
2	ChAdOx1 nCoV-19IBA 01/2023 - 01/2023
2	InterferonsIBA 01/2022 - 11/2020
2	AutoantigensIBA 01/2021 - 01/2020
2	bimagrumabIBA 01/2021 - 01/2019
2	Messenger RNA (mRNA)IBA 01/2020 - 11/2004
2	MicroRNAs (MicroRNA)IBA 01/2020 - 11/2015
2	transcriptional intermediary factor 1IBA 11/2019 - 01/2019
2	Amino Acids FDA Link 11/2019 - 01/2017
2	Certolizumab Pegol FDA Link 06/2019 - 01/2017
2	Amyloid (Amyloid Fibrils)IBA 01/2019 - 07/2015
2	ametantrone (HAQ)IBA 01/2018 - 09/2010
2	TroponinIBA 01/2018 - 05/2015
2	Peptides (Polypeptides)IBA 01/2017 - 04/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 11/2016 - 10/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2015 - 11/2004
1	Uric Acid (Urate)IBA 03/2024
1	Protein Isoforms (Isoforms)IBA 03/2024
1	Prostaglandins AIBA 01/2024
1	Chimeric Antigen ReceptorsIBA 11/2023
1	Abatacept (Orencia)FDA Link 11/2023
1	Intravenous Immunoglobulins (IVIG)FDA Link 05/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2023
1	Immunoglobulin M (IgM)IBA 03/2023
1	zilucoplanIBA 02/2023
1	Complement C4 (Complement Component 4)IBA 02/2023
1	Complement System Proteins (Complement)IBA 02/2023
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 02/2023
1	Signal Recognition ParticleIBA 02/2023
1	Deoxyribonuclease I (Nickase)IBA 01/2023
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2023

Therapy/Procedure

12	Therapeutics 01/2024 - 10/2013
2	Biological Therapy 11/2023 - 02/2014
1	Bariatric Surgery 03/2024
1	Cell- and Tissue-Based Therapy (Cell Therapy) 11/2023